Dataset Information

Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes.

ABSTRACT: Chagas disease (CD) continues to be a major public health burden in Latina America. Information on the interplay between COVID-19 and CD is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD and COVID-19, and to compare it to non-CD patients. Consecutive patients with confirmed COVID-19 were included from March to September 2020. Genetic matching for sex, age, hypertension, diabetes mellitus and hospital was performed in a 4:1 ratio. Of the 7018 patients who had confirmed COVID-19, 31 patients with CD and 124 matched controls were included (median age 72 (64-80) years-old, 44.5% were male). At baseline, heart failure (25.8% vs. 9.7%) and atrial fibrillation (29.0% vs. 5.6%) were more frequent in CD patients than in the controls (p < 0.05). C-reactive protein levels were lower in CD patients compared with the controls (55.5 [35.7, 85.0] vs. 94.3 [50.7, 167.5] mg/dL). In-hospital management, outcomes and complications were similar between the groups. In this large Brazilian COVID-19 Registry, CD patients had a higher prevalence of atrial fibrillation and chronic heart failure compared with non-CD controls, with no differences in-hospital outcomes. The lower C-reactive protein levels in CD patients require further investigation.

SUBMITTER: Molina I

PROVIDER: S-EPMC8514447 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes.

Molina Israel I Marcolino Milena Soriano MS Pires Magda Carvalho MC Ramos Lucas Emanuel Ferreira LEF Silva Rafael Tavares RT Guimarães-Júnior Milton Henriques MH de Oliveira Isaias José Ramos IJR de Carvalho Rafael Lima Rodrigues RLR Nunes Aline Gabrielle Sousa AGS de Barros Ana Lara Rodrigues Monteiro ALRM Scotton Ana Luiza Bahia Alves ALBA Madureira Angélica Aparecida Coelho AAC Farace Bárbara Lopes BL de Carvalho Cíntia Alcantara CA Rodrigues Fernanda d'Athayde FD Anschau Fernando F Botoni Fernando Antonio FA Nascimento Guilherme Fagundes GF Duani Helena H Guimarães Henrique Cerqueira HC de Alvarenga Joice Coutinho JC Moreira Leila Beltrami LB Zandoná Liege Barella LB de Almeida Luana Fonseca LF Oliveira Luana Martins LM Oliveira Luana Martins LM Kopittke Luciane L de Castro Luís César LC Santos Luisa Elem Almeida LEA de Souza Cabral Máderson Alvares MA Ferreira Maria Angélica Pires MAP da Cunha Severino Sampaio Natália N de Oliveira Neimy Ramos NR Assaf Pedro Ledic PL Lopes Sofia Jarjour Tavares Starling SJTS Fereguetti Tatiani Oliveira TO Dos Santos Veridiana Baldon VB de Carvalho Victor Eliel Bastos VEB Ramires Yuri Carlotto YC Ribeiro Antonio Luiz Pinho ALP Moscoso Freddy Antonio Brito FAB Moura Rogério R Polanczyk Carísi Anne CA do Carmo Pereira Nunes Maria M

Scientific reports 20211013 1

Chagas disease (CD) continues to be a major public health burden in Latina America. Information on the interplay between COVID-19 and CD is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD and COVID-19, and to compare it to non-CD patients. Consecutive patients with confirmed COVID-19 were included from March to September 2020. Genetic matching for sex, age, hypertension, diabetes mellitus and hospital was performed in a 4:1 ratio. Of the 7018 ...[more]

PMID: 34645833

Similar Datasets

Project description:We tested the antituberculosis drug SQ109, which is currently in advanced clinical trials for the treatment of drug-susceptible and drug-resistant tuberculosis, for its in vitro activity against the trypanosomatid parasite Trypanosoma cruzi, the causative agent of Chagas disease. SQ109 was found to be a potent inhibitor of the trypomastigote form of the parasite, with a 50% inhibitory concentration (IC50) for cell killing of 50 ± 8 nM, but it had little effect (50% effective concentration [EC50], ∼80 μM) in a red blood cell hemolysis assay. It also inhibited extracellular epimastigotes (IC50, 4.6 ± 1 μM) and the clinically relevant intracellular amastigotes (IC50, ∼0.5 to 1 μM), with a selectivity index of ∼10 to 20. SQ109 caused major ultrastructural changes in all three life cycle forms, as observed by light microscopy, scanning electron microscopy (SEM), and transmission electron microscopy (TEM). It rapidly collapsed the inner mitochondrial membrane potential (Δψm) in succinate-energized mitochondria, acting in the same manner as the uncoupler FCCP [carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone], and it caused the alkalinization of internal acidic compartments, effects that are likely to make major contributions to its mechanism of action. The compound also had activity against squalene synthase, binding to its active site; it inhibited sterol side-chain reduction and, in the amastigote assay, acted synergistically with the antifungal drug posaconazole, with a fractional inhibitory concentration index (FICI) of 0.48, but these effects are unlikely to account for the rapid effects seen on cell morphology and cell killing. SQ109 thus most likely acts, at least in part, by collapsing Δψ/ΔpH, one of the major mechanisms demonstrated previously for its action against Mycobacterium tuberculosis. Overall, the results suggest that SQ109, which is currently in advanced clinical trials for the treatment of drug-susceptible and drug-resistant tuberculosis, may also have potential as a drug lead against Chagas disease.

Dataset Information

Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes.

Publications

Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets